Laura Panjwani

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial.

Jonathan Riess emphasizes the importance of testing for ROS1 and TRK in patients with lung cancer so that treatment options can be explored accordingly.

Though it is a difficult subtype to treat right now, Cynthia Ma is optimistic about emerging treatment options for triple-negative breast cancer.

In treating low-risk breast cancer, adding novel agents isn't always necessary, Hope S. Rugo says.

The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy.

The FDA approved the Roche cobas HPV Test for use with SurePath Preservative Fluid.

Bone metastases often create significant problems for patients with advanced prostate cancer, according to Neal Shore.

Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).

The need for new treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is dire, says Ranee Mehra.

Deciding on treatment for melanoma does not have to be a guessing game, says Keith T. Flaherty.

Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.

Final five-year efficacy and safety data of the JAK-2 inhibitor, Jakafi, confirmed previous findings of the treatment's benefit for patients with myelofibrosis.

A recent study identified the optimal time for certain patients with CML to stop TKI treatment.

When Darzalex was added to Velcade and dexamethasone, patients with relapsed multiple myeloma had a reduced risk of disease progression or death, according to a recent phase 3 trial.

Aggressive end-of-life care is often harmful to patients and their families, yet is still so widely used.

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study.

Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant, compared with patients who received chemotherapy alone.

Immunotherapy is showing promise for treatment of head and neck cancer who progress after chemotherapy, though there is still a long way to go, says Robert Ferris.

The immunotherapy combination of Opdivo and Yervoy continues to show promise as it presented overall survival benefits for patients with advanced melanoma.

A recent phase 3 trial is exploring the question of whether or not smoldering multiple myeloma needs treatment.

“There are a lot of drugs, many targets, and still no cures,” says Figlin. “There is still an unmet need, despite the plethora of agents that have been approved in this space.”

In an interview with CURE, DeMichele explains the significance of the I-SPY 2 data, the advantages of Kadcyla versus standard of care and what is on the horizon for the use of Kadcyla in HER2-positive disease.

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.

An interview with Jason Luke, an assistant professor of Medicine at the University of Chicago Medicine, reveals that he thinks immunotherapy should become a main treatment for many patients with melanoma.

As treatments for kidney cancer continue to evolve, oncologists, surgeons and patients are faced with a number of questions.

Four new drugs were approved in 2015 to treat multiple myeloma, and Sundar Jagannath is optimistic about the coming years.

Although immunotherapies have been approved for use for patients with metastatic melanoma, doctors are still apprehensive to use them as a frontline treatment option.

The landscape for treating CLL is changing, bringing about questions and hope for a cure.

Several new tests for prostate cancer are on the market. When used alongside PSA screenings, they can provide a much more straightforward insight into prostate cancer risk.